• 40 countries

• New sites added to regions since we began:

CCASAnet – Mexico West Africa – Nigeria Southern Africa – Zambia Asia – Vietnam

• NA-ACCORD – When to start• CCASAnet – Mortality; site assessments • East Africa – LTFU • Central Africa – Discordant couples; ETOH• Southern Africa – IRIS, Peds ART outcomes • West Africa – pediatric mortality on ART• Asia – ART and anemia (1st global concept);

HBV & HCV impact on HIV outcomes

Cancer, Heart and Kidney disease - Understanding the impact on HIV (CHK-UP on HIV)

Customized Computer Software for EMR (CCASA)

Increased Analytic Capacity in REACT (East and Southern Africa)

Open MRS System Development (East Africa)

IeDEA adds Malaria• Malaria surveillance at “Network Trial sites” with epidemiology led

by IeDEA investigators• Collaboration with DMID

*American Recovery and Reinvestment Act of 2009

ARRA* Initiatives

NIH/PEPFAR Supplements

• Implementation Science– Inform programs: efficiency, effectiveness– Impact evaluation

• Limited Competition– Current grantees; no limit to # of applications– Research at PEPFAR funded sites (direct/indirect)

• 5-page concepts

• 1-year projects only (potential for carry forward x1 yr)

•IeDEA II (funding starts 2011)•Enhance analytical capacity - complex analysis•Manage impact of loss to follow-up•Selected enhancements of data: adverse events, mortality, risk behaviors•Strengthen links to other programs: Cancer, TB, PMTCT, Pediatric to Adult•Expand to cover the “Big 3 +” (HIV, Malaria, TB, hepatitis)

IeDEA RFA what is knowable(today that is)

Dates to keep in mind• Published mid July 2010• Due mid November 2010• Reviewed winter 2010/2011• Awarded spring/summer 2011Funding• Slightly more money overall• Same institutes (at least) NIAID, NCI, NICHDNew Format

Background and Significance

Research Strategy

a. Significance

b. Innovation

c. Approach• Preliminary Studies

for New Applications• Progress Report for

Renewal/Revision

Research Design and

Methods

Preliminary Studies/Progress Report

Old Application New Application

RESTRUCTURED RESEARCH PLAN

Other SectionsPersonal Statement: Tell us why your experience and

qualifications make you particularly well-suited for your role in the project

• Publications: Will be encouraged to include no more than 15 using recency, importance to the field, and/or relevancy to the application

• Total Biosketch will still be limited to 4 pages, including the education table at the top

Environment - Address how the scientific environment will contribute to probability of success of the project, unique features of the environment, etc. For ESIs, provide a description of the institutional investment in the success of the investigator.

http://odoerdb2.od.nih.gov/PeerReview/Revised_Page_Limits.pdf